IRIDEX Corporation (IRIX)
1.63
0.00 (0.00%)
At close: Jan 14, 2025, 3:59 PM
1.61
-1.04%
After-hours Jan 14, 2025, 03:59 PM EST
undefined% (undefined)
| Bid | 1.55 |
| Market Cap | 27.12M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.67 |
| PE Ratio (ttm) | -2.43 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 1.64 |
| Volume | 46,125 |
| Avg. Volume (20D) | 37,934 |
| Open | 1.66 |
| Previous Close | 1.63 |
| Day's Range | 1.61 - 1.66 |
| 52-Week Range | 1.27 - 3.65 |
| Beta | undefined |
About IRIX
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuL...
Industry Medical - Devices
Sector Healthcare
IPO Date Feb 16, 1996
Employees 111
Stock Exchange NASDAQ
Ticker Symbol IRIX
Website https://www.iridex.com
Analyst Forecast
According to 1 analyst ratings, the average rating for IRIX stock is "Hold." The 12-month stock price forecast is $2, which is an increase of 22.70% from the latest price.
Buy 0.00%
Hold 100.00%
Sell 0.00%
Next Earnings Release
IRIDEX Corporation is scheduled to release its earnings on Mar 25, 2025,
during market hours.
Analysts project revenue of $12.80M, reflecting a 2.75% YoY growth and earnings per share of -0.05, making a -72.22% decrease YoY.
Analysts project revenue of $12.80M, reflecting a 2.75% YoY growth and earnings per share of -0.05, making a -72.22% decrease YoY.
2 months ago ·
Source
+34.04%
IRIDEX shares are trading higher. The company repo...
Unlock content with
Pro Subscription
8 months ago ·
Source
-13.96%
IRIDEX shares are trading lower after the company reported worse-than-expected Q1 financial results.
